Analysis of upfront resection or stereotactic radiosurgery for local control of solid and cystic cerebellar hemangioblastomas

医学 放射外科 血管母细胞瘤 单变量分析 外科 肿瘤进展 回顾性队列研究 多元分析 放射科 癌症 放射治疗 内科学
作者
Luis R. Carrete,Ramin A. Morshed,Jacob S. Young,Lauro N. Avalos,Penny K. Sneed,Manish K. Aghi,Michael W. McDermott,Philip V. Theodosopoulos
出处
期刊:Journal of Neurosurgery [Journal of Neurosurgery Publishing Group]
卷期号:140 (2): 404-411 被引量:2
标识
DOI:10.3171/2023.6.jns222629
摘要

OBJECTIVE The purpose of this study was to identify rates of and risk factors for local tumor progression in patients who had undergone surgery or radiosurgery for the management of cerebellar hemangioblastoma and to describe treatments pursued following tumor progression. METHODS The authors conducted a retrospective single-center review of patients who had undergone treatment of a cerebellar hemangioblastoma with either surgery or stereotactic radiosurgery (SRS) between 1996 and 2019. Univariate and multivariate regression analyses were performed to examine factors associated with local tumor control. RESULTS One hundred nine patients met the study inclusion criteria. Overall, these patients had a total of 577 hemangioblastomas, 229 of which were located in the cerebellum. The surgical and SRS cohorts consisted of 106 and 123 cerebellar hemangioblastomas, respectively. For patients undergoing surgery, tumors were treated with subtotal resection and gross-total resection in 5.7% and 94.3% of cases, respectively. For patients receiving SRS, the mean target volume was 0.71 cm 3 and the mean margin dose was 18.0 Gy. Five-year freedom from lesion progression for the surgical and SRS groups was 99% and 82%, respectively. The surgical and SRS cohorts contained 32% versus 97% von Hippel–Lindau tumors, 78% versus 7% cystic hemangioblastomas, and 12.8- versus 0.56-cm 3 mean tumor volumes, respectively. On multivariate analysis, factors associated with local tumor progression in the SRS group included older patient age (HR 1.06, 95% CI 1.03–1.09, p < 0.001) and a cystic component (HR 9.0, 95% CI 2.03–32.0, p = 0.001). Repeat SRS as salvage therapy was used more often for smaller tumor recurrences, and no tumor recurrences of < 1.0 cm 3 required additional salvage surgery following repeat SRS. CONCLUSIONS Both surgery and SRS achieve high rates of local control of hemangioblastomas. Age and cystic features are associated with local progression after SRS treatment for cerebellar hemangioblastomas. In cases of local tumor recurrence, salvage surgery and repeat SRS are valid forms of treatment to achieve local tumor control, although resection may be preferable for larger recurrences.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
寒冷丹雪完成签到,获得积分10
2秒前
3秒前
CodeCraft应助nqterysc采纳,获得10
6秒前
BaooooooMao完成签到,获得积分10
6秒前
量子星尘发布了新的文献求助10
7秒前
浩气长存完成签到 ,获得积分10
7秒前
arsenal完成签到 ,获得积分10
7秒前
儒雅黑裤完成签到,获得积分10
8秒前
勤奋雨完成签到,获得积分10
9秒前
辛勤谷雪完成签到,获得积分0
9秒前
mumuaidafu完成签到 ,获得积分10
9秒前
《子非鱼》完成签到,获得积分10
10秒前
花白年华哈哈哈完成签到,获得积分10
11秒前
李大王完成签到 ,获得积分10
11秒前
ludong_0完成签到,获得积分10
12秒前
13秒前
辛勤如柏完成签到,获得积分10
14秒前
14秒前
14秒前
14秒前
14秒前
Ava应助科研通管家采纳,获得30
14秒前
科研通AI6应助科研通管家采纳,获得10
14秒前
14秒前
科研通AI2S应助科研通管家采纳,获得10
14秒前
大仙完成签到,获得积分10
17秒前
fang完成签到,获得积分10
19秒前
喜凉的采枫完成签到 ,获得积分10
19秒前
钱塘郎中完成签到,获得积分0
20秒前
凶狠的土豆丝完成签到 ,获得积分10
20秒前
日照金峰完成签到,获得积分10
21秒前
LD完成签到 ,获得积分10
21秒前
21秒前
NexusExplorer应助Maestro_S采纳,获得10
22秒前
23秒前
科研通AI6.1应助马成双采纳,获得10
23秒前
量子星尘发布了新的文献求助10
23秒前
绵绵完成签到,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Encyclopedia of Forensic and Legal Medicine Third Edition 5000
Introduction to strong mixing conditions volume 1-3 5000
Agyptische Geschichte der 21.30. Dynastie 3000
Aerospace Engineering Education During the First Century of Flight 2000
从k到英国情人 1700
„Semitische Wissenschaften“? 1510
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5773484
求助须知:如何正确求助?哪些是违规求助? 5611745
关于积分的说明 15431379
捐赠科研通 4905949
什么是DOI,文献DOI怎么找? 2639966
邀请新用户注册赠送积分活动 1587841
关于科研通互助平台的介绍 1542900